Harbour BioMed Partner Spruce Biosciences Separates CRHX-101 Program into Adrenyx Biosciences
· GlobeWire Daily Business Desk · Source: www.prnewswire.com

Original GlobeWire Daily editorial illustration — not an event photograph.
Harbour BioMed announced that its partner, Spruce Biosciences, has separated its CRHX-101 program into a newly established, wholly-owned subsidiary named Adrenyx Biosciences. This corporate restructuring aims to advance the development of the CRHX-101 antibody through a dedicated standalone company focusing on endocrinology.
CRHX-101, which originated from Harbour BioMed's incubated entity HBM Alpha Therapeutics, is a monoclonal antibody designed to selectively neutralize corticotropin-releasing hormone as a potential treatment for congenital adrenal hyperplasia. Adrenyx is expected to be listed on Nasdaq in the first half of 2027, subject to customary processes and planning.
Corporate Restructuring and Future Plans
- Subsidiary Establishment: Adrenyx Biosciences is formed as a wholly-owned subsidiary of Spruce Biosciences focused entirely on endocrinology.
- Expected Nasdaq Listing: Adrenyx is anticipated to be listed on Nasdaq in the first half of 2027.
- Shareholder Distribution: Following a planned pro rata distribution of Adrenyx common stock to Spruce shareholders, Harbour BioMed expects to hold equity interests in both Spruce and Adrenyx.
Development Focus and Financing
- Target Indication: CRHX-101 targets corticotropin-releasing hormone to address adrenal androgen excess in classic congenital adrenal hyperplasia.
- Near-Term Priorities: Activities include completing IND-enabling nonclinical and chemistry, manufacturing, and controls work, filing an Investigational New Drug application with the U.S. FDA, and initiating a clinical program.
- Financial Support: Adrenyx has secured an initial US$5 million through a secured convertible note purchase arrangement, with potential for up to US$10 million in aggregate principal, alongside a planned private placement of equity securities expected to be completed in connection with the distribution.
Verification and Practical Implications
Stakeholders and interested parties can verify official announcements and corporate updates by consulting regulatory filings on Nasdaq or visiting the official Harbour BioMed website at www.harbourbiomed.com. Readers should note that corporate restructuring, expected listings, and clinical developments remain subject to planned timelines and regulatory approvals.
AI-assisted reporting; source claims are attributed and have not been independently verified.



